Affymax Unveils Phase 3 Program Update Hematide
Affymax has reported that it has informed clinical trial sites to complete treatment of patients in the phase 3 clinical program for the investigational drug, Hematide, by the
Gilead Sciences has opened a new 182,000ft² research centre at its Foster City headquarters in California, US, for advancing medicines to treat challenging diseases.